BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12641381)

  • 1. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture.
    Takahashi E; Mukohyama H; Aoki K; Duarte WR; Lerner UH; Ohya K; Omura K; Kasugai S
    J Med Dent Sci; 2002 Dec; 49(4):109-20. PubMed ID: 12641381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
    Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
    J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K; Hirukawa K; Nakamura H; Togari A
    Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
    Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
    Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption.
    Heinrich J; Bsoul S; Barnes J; Woodruff K; Abboud S
    Arch Oral Biol; 2005 Oct; 50(10):897-908. PubMed ID: 16137499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
    Suzuki T; Suda N; Ohyama K
    J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells.
    Hasegawa T; Yoshimura Y; Kikuiri T; Yawaka Y; Takeyama S; Matsumoto A; Oguchi H; Shirakawa T
    J Periodontal Res; 2002 Dec; 37(6):405-11. PubMed ID: 12472833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.